

Michael Stowasser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4463057/publications.pdf>

Version: 2024-02-01

148
papers

12,179
citations

36303

51
h-index

26613

107
g-index

151
all docs

151
docs citations

151
times ranked

5681
citing authors

#	ARTICLE	IF	CITATIONS
1	2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action. Journal of Human Hypertension, 2023, 37, 428-437.	2.2	22
2	Aldosterone-producing adenoma associated with non-suppressed renin: a case series. Journal of Human Hypertension, 2022, 36, 373-380.	2.2	4
3	Detecting primary aldosteronism in Australian primary care: a prospective study. Medical Journal of Australia, 2022, 216, 408-412.	1.7	29
4	The Cl ⁻ /HCO ₃ ⁻ exchanger pendrin is downregulated during oral co-administration of exogenous mineralocorticoid and KCl in patients with primary aldosteronism. Journal of Human Hypertension, 2021, 35, 837-848.	2.2	14
5	Aldosterone, gut microbiome and hypertension: selected papers from APCH 2019. Journal of Human Hypertension, 2021, 35, 109-109.	2.2	0
6	The mineralocorticoid receptor—an emerging player in metabolic syndrome?. Journal of Human Hypertension, 2021, 35, 117-123.	2.2	20
7	ClearSight [®] , a finger cuff versus invasive arterial pressure measurement in patients with body mass index above 45 kg/m ² . BMC Anesthesiology, 2021, 21, 152.	1.8	6
8	Relationship Between the Aldosterone-to-Renin Ratio and Blood Pressure in Young Adults: A Longitudinal Study. Hypertension, 2021, 78, 387-396.	2.7	6
9	Aldosterone and Primary Aldosteronism: Star Performers in Hypertension Research. Hypertension, 2021, 78, 747-750.	2.7	0
10	Diagnosis and treatment of primary aldosteronism. Lancet Diabetes and Endocrinology, 2021, 9, 876-892.	11.4	106
11	Diagnosis of Primary Aldosteronism by Seated Saline Suppression Test—Variability Between Immunoassay and HPLC-MS/MS. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e477-e483.	3.6	35
12	The Role of Exercise in Patients with Obesity and Hypertension. Current Hypertension Reports, 2020, 22, 77.	3.5	15
13	Managing hypertension during the COVID-19 pandemic. Journal of Human Hypertension, 2020, 34, 415-417.	2.2	19
14	Can unilateral forms of primary aldosteronism be excluded with confidence preoperatively by methods other than adrenal venous sampling? The search continues. Journal of Hypertension, 2020, 38, 1259-1261.	0.5	1
15	Effects of Ramipril on the Aldosterone/Renin Ratio and the Aldosterone/Angiotensin II Ratio in Patients With Primary Aldosteronism. Hypertension, 2020, 76, 488-496.	2.7	23
16	Biochemical, Histopathological, and Genetic Characterization of Posture-Responsive and Unresponsive APAs. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3224-e3235.	3.6	21
17	Measurement of Equilibrium Angiotensin II in the Diagnosis of Primary Aldosteronism. Clinical Chemistry, 2020, 66, 483-492.	3.2	44
18	Controversies and advances in adrenal venous sampling in the diagnostic workup of primary aldosteronism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101400.	4.7	24

#	ARTICLE	IF	CITATIONS
19	Exercise and sport science australia position stand update on exercise and hypertension. Journal of Human Hypertension, 2019, 33, 837-843.	2.2	47
20	Strengthening a societal tie and other new initiatives for 2019. Journal of Human Hypertension, 2019, 33, 173-173.	2.2	0
21	Pathogenesis of Familial Hyperaldosteronism Type II: New Concepts Involving Anion Channels. Current Hypertension Reports, 2019, 21, 31.	3.5	19
22	The interplay of renal potassium and sodium handling in blood pressure regulation: critical role of the WNK-SPAK-NCC pathway. Journal of Human Hypertension, 2019, 33, 508-523.	2.2	21
23	Response to Letter to the Editor: "Comparison of Seated With Recumbent Saline Suppression Testing for the Diagnosis of Primary Aldosteronism". Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2344-2345.	3.6	0
24	Mineralocorticoid antagonism enhances brown adipose tissue function in humans: A randomized placebo-controlled crossover study. Diabetes, Obesity and Metabolism, 2019, 21, 509-516.	4.4	40
25	Primary Aldosteronism; Epidemiology and Screening. , 2019, , 598-606.		1
26	CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nature Genetics, 2018, 50, 349-354.	21.4	188
27	Cellular and Genetic Causes of Idiopathic Hyperaldosteronism. Hypertension, 2018, 72, 874-880.	2.7	137
28	Aldosterone LC-MS/MS Assay-Specific Threshold Values in Screening and Confirmatory Testing for Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3965-3973.	3.6	40
29	Comparison of Seated With Recumbent Saline Suppression Testing for the Diagnosis of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4113-4124.	3.6	68
30	A young man with severe hypertension. BMJ: British Medical Journal, 2018, 362, k2935.	2.3	1
31	In Primary Aldosteronism, Mineralocorticoids Influence Exosomal Sodium-Chloride Cotransporter Abundance. Journal of the American Society of Nephrology: JASN, 2017, 28, 56-63.	6.1	55
32	New Advances in the Diagnostic Workup of Primary Aldosteronism. Journal of the Endocrine Society, 2017, 1, 149-161.	0.2	10
33	Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement. Endocrine Reviews, 2017, 38, 103-122.	20.1	76
34	Effect of Moxonidine on the Aldosterone/Renin Ratio in Healthy Male Volunteers. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2039-2043.	3.6	18
35	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes and Endocrinology, 2017, 5, 689-699.	11.4	595
36	Effect of Combined Hormonal Replacement Therapy on the Aldosterone/Renin Ratio in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2329-2334.	3.6	24

#	ARTICLE	IF	CITATIONS
37	Targeted LOWering of Central Blood Pressure in patients with hypertension: Baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study). Contemporary Clinical Trials, 2017, 62, 37-42.	1.8	8
38	Can Screening and Confirmatory Testing in the Management of Patients with Primary Aldosteronism be Improved?. Hormone and Metabolic Research, 2017, 49, 915-921.	1.5	23
39	Potassium Channel Mutations and Human Disease. , 2017, , 503-516.		0
40	Guiding Hypertension Management Using Central Blood Pressure: Effect of Medication Withdrawal on Left Ventricular Function. American Journal of Hypertension, 2016, 29, 319-325.	2.0	8
41	OS 35-04 THE AA2-RATIO. Journal of Hypertension, 2016, 34, e400.	0.5	1
42	Resistant Hypertension and Chronic Kidney Disease: a Dangerous Liaison. Current Hypertension Reports, 2016, 18, 36.	3.5	17
43	Blood Pressure Variability and Prediction of Target Organ Damage in Patients With Uncomplicated Hypertension. American Journal of Hypertension, 2016, 29, 1046-1054.	2.0	25
44	Is It the Beginning of the End for the Recumbent Saline Infusion Test?. Hypertension, 2016, 68, 857-858.	2.7	1
45	Primary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney. Physiological Reviews, 2016, 96, 1327-1384.	28.8	119
46	Comparison of Central Blood Pressure Estimated by a Cuff-Based Device With Radial Tonometry. American Journal of Hypertension, 2016, 29, 1173-1178.	2.0	21
47	Does <scp>ACTH</scp> improve the diagnostic performance of adrenal vein sampling for subtyping primary aldosteronism?. Clinical Endocrinology, 2016, 85, 703-709.	2.4	47
48	The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1889-1916.	3.6	1,921
49	The utility of renal venous renin studies in selection of patients with renal artery stenosis for angioplasty. Journal of Hypertension, 2015, 33, 1931-1938.	0.5	5
50	Should aldosterone suppression tests be conducted during a particular phase of the menstrual cycle, and, if so, which phase? Results of a preliminary study. Clinical Endocrinology, 2015, 83, 303-307.	2.4	25
51	Does concomitant autonomous adrenal cortisol overproduction have the potential to confound the interpretation of adrenal venous sampling in primary aldosteronism?. Clinical Endocrinology, 2015, 83, 456-461.	2.4	31
52	Adrenal Venous Sampling for Differentiating Unilateral From Bilateral Primary Aldosteronism. Hypertension, 2015, 65, 704-706.	2.7	6
53	Update in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1-10.	3.6	62
54	Does Contralateral Suppression at Adrenal Venous Sampling Predict Outcome Following Unilateral Adrenalectomy for Primary Aldosteronism? A Retrospective Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1477-1484.	3.6	83

#	ARTICLE	IF	CITATIONS
55	Use of plasma metanephrine to aid adrenal venous sampling in combined aldosterone and cortisol over-secretion. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 150075.	0.5	12
56	Detection of mutations in <i>KLHL3</i> and <i>CUL3</i> in families with FHt (familial hyperkalaemic) Tj ETQq0 0 0 rgBT /Overlock 10 T	4.3	49
57	Role for Germline Mutations and a Rare Coding Single Nucleotide Polymorphism Within the KCNJ5 Potassium Channel in a Large Cohort of Sporadic Cases of Primary Aldosteronism. Hypertension, 2014, 63, 783-789.	2.7	58
58	Aldosterone Excess and Resistant Hypertension: Investigation and Treatment. Current Hypertension Reports, 2014, 16, 439.	3.5	11
59	Seated Saline Suppression Testing For The Diagnosis Of Primary Aldosteronism: A Preliminary Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2745-2753.	3.6	96
60	The Aldosteroneâ€“Renin Ratio: Role and Problems. , 2014, , 109-126.		1
61	Familial Hyperaldosteronism Type II. , 2014, , 87-97.		0
62	Quality-of-Life Aspects of Primary Aldosteronism. , 2014, , 197-207.		0
63	The Renaissance of Primary Aldosteronism: What Has it Taught Us?. Heart Lung and Circulation, 2013, 22, 412-420.	0.4	8
64	Diagnosis and management of primary aldosteronism: An updated review. Annals of Medicine, 2013, 45, 375-383.	3.8	111
65	A Randomized Trial of Dietary Sodium Restriction in CKD. Journal of the American Society of Nephrology: JASN, 2013, 24, 2096-2103.	6.1	253
66	Repeating adrenal vein sampling when neither aldosterone/cortisol ratio exceeds peripheral yields a high incidence of aldosterone-producing adenoma. Journal of Hypertension, 2013, 31, 2005-2009.	0.5	27
67	Primary aldosteronism and potassium channel mutations. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 170-179.	2.3	7
68	Increased Dietary Sodium Is Related to Severity of Obstructive Sleep Apnea in Patients With Resistant Hypertension and Hyperaldosteronism. Chest, 2013, 143, 978-983.	0.8	61
69	Adverse Cardiovascular Outcomes of Corticosteroid Excess. Endocrinology, 2012, 153, 5137-5142.	2.8	30
70	Somatic Mutations Affecting the Selectivity Filter of KCNJ5 Are Frequent in 2 Large Unselected Collections of Adrenal Aldosteronomas. Hypertension, 2012, 59, 587-591.	2.7	139
71	Improving the Success and Reliability of Adrenal Venous Sampling: Focus on Intraprocedural Cortisol Measurement. Clinical Chemistry, 2012, 58, 1275-1277.	3.2	14
72	Towards a better understanding of causation and consequences. Nature Reviews Endocrinology, 2012, 8, 70-72.	9.6	11

#	ARTICLE	IF	CITATIONS
73	Calibrators for measuring aldosterone by liquid chromatography-tandem mass spectrometry. <i>Clinica Chimica Acta</i> , 2012, 413, 346-347.	1.1	5
74	The Adrenal Vein Sampling International Study (AVIS) for Identifying the Major Subtypes of Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1606-1614.	3.6	310
75	Familial or Genetic Primary Aldosteronism and Gordon Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2011, 40, 343-368.	3.2	25
76	Effect of Contraceptives on Aldosterone/Renin Ratio May Vary According to the Components of Contraceptive, Renin Assay Method, and Possibly Route of Administration. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1797-1804.	3.6	80
77	Quality of Life in Patients with Bilateral Primary Aldosteronism before and during Treatment with Spironolactone and/or Amiloride, Including a Comparison with Our Previously Published Results in Those with Unilateral Disease Treated Surgically. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2904-2911.	3.6	90
78	Cardiac Dimensions Are Largely Determined by Dietary Salt in Patients with Primary Aldosteronism: Results of a Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2813-2820.	3.6	72
79	What is new in the management of resistant hypertension?. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 261-273.	0.2	2
80	Effects of Two Selective Serotonin Reuptake Inhibitor Antidepressants, Sertraline and Escitalopram, on Aldosterone/Renin Ratio in Normotensive Depressed Male Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1039-1045.	3.6	41
81	Are Women More at Risk of False-Positive Primary Aldosteronism Screening and Unnecessary Suppression Testing than Men?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E340-E346.	3.6	86
82	Simultaneous measurement of aldosterone and cortisol by high-performance liquid chromatography-tandem mass spectrometry: Application to dehydration-rehydration studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 1195-1198.	2.3	31
83	Improved Quality of Life, Blood Pressure, and Biochemical Status Following Laparoscopic Adrenalectomy for Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1360-1364.	3.6	147
84	Effect of Atenolol on Aldosterone/Renin Ratio Calculated by Both Plasma Renin Activity and Direct Renin Concentration in Healthy Male Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3201-3206.	3.6	44
85	Impact of Different Diagnostic Criteria During Adrenal Vein Sampling on Reproducibility of Subtype Diagnosis in Patients With Primary Aldosteronism. <i>Hypertension</i> , 2010, 55, 667-673.	2.7	140
86	Laboratory investigation of primary aldosteronism. <i>Clinical Biochemist Reviews</i> , 2010, 31, 39-56.	3.3	63
87	Activity Assays and Immunoassays for Plasma Renin and Prorenin: Information Provided and Precautions Necessary for Accurate Measurement. <i>Clinical Chemistry</i> , 2009, 55, 867-877.	3.2	172
88	Commentary. <i>Clinical Chemistry</i> , 2009, 55, 2097-2097.	3.2	0
89	Update in Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3623-3630.	3.6	93
90	Role of Unilateral Adrenalectomy in Bilateral Primary Aldosteronism: A 22-Year Single Center Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2437-2445.	3.6	130

#	ARTICLE	IF	CITATIONS
91	Elevated Serum Interleukin 6 Levels in Normotensive Individuals With Familial Hyperaldosteronism Type 1. Hypertension, 2009, 53, e31-2.	2.7	23
92	Measurement of Aldosterone in Human Plasma by Semiautomated HPLC–Tandem Mass Spectrometry. Clinical Chemistry, 2009, 55, 1155-1162.	3.2	109
93	Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3266-3281.	3.6	1,440
94	Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. Journal of Hypertension, 2008, 26, 1577-1582.	0.5	82
95	Primary aldosteronism: the case for screening. Nature Clinical Practice Nephrology, 2007, 3, 582-583.	2.0	20
96	Aldosterone Excess, Hypertension, and Chromosome 7p22. Hypertension, 2007, 49, 761-762.	2.7	7
97	Genetic Forms of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 75-81.	2.2	4
98	Monogenic mineralocorticoid hypertension. Best Practice and Research in Clinical Endocrinology and Metabolism, 2006, 20, 401-420.	4.7	17
99	No evidence for coding region mutations in the retinoblastoma-associated Kruppel-associated box protein gene (RBaK) causing familial hyperaldosteronism type II. Clinical Endocrinology, 2006, 65, 829-831.	2.4	13
100	Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. Journal of Hypertension, 2005, 23, 1477-1484.	0.5	85
101	Evidence for Abnormal Left Ventricular Structure and Function in Normotensive Individuals with Familial Hyperaldosteronism Type I. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5070-5076.	3.6	230
102	Effect of Aldosterone Antagonism on Myocardial Dysfunction in Hypertensive Patients With Diastolic Heart Failure. Circulation, 2004, 110, 558-565.	1.6	276
103	Genomic structure of the human gene for protein kinase A regulatory subunit R1-beta (PRKAR1B) on 7p22: no evidence for mutations in familial hyperaldosteronism type II in a large affected kindred. Clinical Endocrinology, 2004, 61, 716-723.	2.4	18
104	Increased Diagnosis of Primary Aldosteronism, Including Surgically Correctable Forms, in Centers from Five Continents. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1045-1050.	3.6	862
105	Primary aldosteronism—careful investigation is essential and rewarding. Molecular and Cellular Endocrinology, 2004, 217, 33-39.	3.2	167
106	The Aldosterone/Renin Ratio in Screening for Primary Aldosteronism. , 2004, 14, 267-276.		36
107	Primary aldosteronism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2003, 17, 591-605.	4.7	55
108	Primary aldosteronism: from genesis to genetics. Trends in Endocrinology and Metabolism, 2003, 14, 310-317.	7.1	46

#	ARTICLE	IF	CITATIONS
109	High rate of detection of primary aldosteronism, including surgically treatable forms, after ???non-selective??? screening of hypertensive patients. Journal of Hypertension, 2003, 21, 2149-2157.	0.5	225
110	A Randomised Controlled Trial of Medication Liaison Servicesâ€™Patient Outcomes. Journal of Pharmacy Practice and Research, 2002, 32, 133-140.	0.8	87
111	A Randomised Controlled Trial of Medication Liaison Servicesâ€™Acceptance and Use by Health Professionals. Journal of Pharmacy Practice and Research, 2002, 32, 221-226.	0.8	11
112	Familial hyperaldosteronism. Journal of Steroid Biochemistry and Molecular Biology, 2001, 78, 215-229.	2.5	92
113	Primary aldosteronism: Rare bird or common cause of secondary hypertension?. Current Hypertension Reports, 2001, 3, 230-239.	3.5	34
114	Prevalence and diagnostic workup of primary aldosteronism: new knowledge and new approaches. Nephrology, 2001, 6, 119-126.	1.6	23
115	New Perspectives On The Role Of Aldosterone Excess In Cardiovascular Disease. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 783-791.	1.9	58
116	Familial Varieties Of Primary Aldosteronism. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 1087-1090.	1.9	29
117	Primary aldosteronism: Are we diagnosing and operating on too few patients?. World Journal of Surgery, 2001, 25, 941-947.	1.6	87
118	Review: Diagnosis and management of primary aldosteronism. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, 156-169.	1.7	156
119	How common is adrenal-based mineralocorticoid hypertension?. Current Opinion in Endocrinology, Diabetes and Obesity, 2000, 7, 143-150.	0.6	6
120	Primary aldosteronism. Journal of Hypertension, 2000, 18, 1165-1176.	0.5	71
121	Severity of Hypertension in Familial Hyperaldosteronism Type I: Relationship to Gender and Degree of Biochemical Disturbance ¹ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2160-2166.	3.6	54
122	Treatment of Familial Hyperaldosteronism Type I: Only Partial Suppression of Adrenocorticotropin Required to Correct Hypertension. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3313-3318.	3.6	81
123	Treatment of Familial Hyperaldosteronism Type I: Only Partial Suppression of Adrenocorticotropin Required to Correct Hypertension. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3313-3318.	3.6	27
124	Biochemical Evidence of Aldosterone Overproduction and Abnormal Regulation in Normotensive Individuals with Familial Hyperaldosteronism Type I ¹ . Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4031-4036.	3.6	44
125	Success of Surgery for Primary Aldosteronism Judged by Residual Autonomous Aldosterone Production. World Journal of Surgery, 1998, 22, 1243-1245.	1.6	80
126	Familial Forms Broaden the Horizons for Primary Aldosteronism. Trends in Endocrinology and Metabolism, 1998, 9, 220-227.	7.1	35

#	ARTICLE	IF	CITATIONS
127	Expression of 11 β HSD-2 in human adrenal cortical carcinoma and adenoma. Endocrine Research, 1998, 24, 875-876.	1.2	8
128	Familial Hyperaldosteronism Type II: Description of a Large Kindred and Exclusion of the Aldosterone Synthase (CYP11B2) Gene ^{<sup>1</sup>. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3214-3218.}	3.6	71
129	In Familial Hyperaldosteronism Type I, Hybrid Gene-Induced Aldosterone Production Dominates That Induced by Wild-Type Genes ^{<sup>1</sup>. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3670-3676.}	3.6	18
130	Laparoscopic Adrenalectomy. World Journal of Surgery, 1996, 20, 758-761.	1.6	87
131	PRODUCTION OF 18 α -OXO α -CORTISOL IN SUBTYPES OF PRIMARY ALDOSTERONISM. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 591-593.	1.9	36
132	DIFFERENT ALLELIC PATTERNS AT CHROMOSOME 11q13 IN PAIRED ALDOSTERONE-PRODUCING TUMOURS AND BLOOD DNA. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 594-596.	1.9	15
133	Allelic losses on chromosome band 11q13 in aldosterone-producing adrenal tumors. Genes Chromosomes and Cancer, 1995, 12, 73-75.	2.8	49
134	HYBRID GENE OR HYBRID STEROIDS IN THE DETECTION AND SCREENING FOR FAMILIAL HYPERALDOSTERONISM TYPE I. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 444-446.	1.9	9
135	PLASMA ALDOSTERONE RESPONSE TO ACTH IN SUBTYPES OF PRIMARY ALDOSTERONISM. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 460-462.	1.9	24
136	ANALYSIS OF THE RENIN GENE IN PATIENTS WITH ALDOSTERONE-PRODUCING ADENOMAS BY POLYMERASE CHAIN REACTION-SINGLE STRANDED CONFORMATIONAL POLYMORPHISMS AND LONG POLYMERASE CHAIN REACTION. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 484-486.	1.9	2
137	LAPAROSCOPIC ADRENALECTOMY FOR ADRENAL TUMOURS CAUSING HYPERTENSION AND FOR 'INCIDENTALOMAS' OF THE ADRENAL ON COMPUTERIZED TOMOGRAPHY SCANNING. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 490-492.	1.9	23
138	Primary aldosteronism—some genetic, morphological, and biochemical aspects of subtypes. Steroids, 1995, 60, 35-41.	1.8	59
139	Reduced Renal Extraction of Atrial Natriuretic Peptide in Primary Aldosteronism. Hypertension, 1995, 26, 624-627.	2.7	3
140	GENETICS OF PRIMARY ALDOSTERONISM. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 915-918.	1.9	10
141	RENAL EXTRACTION OF ATRIAL NATRIURETIC PEPTIDE IN UNILATERAL RENAL ARTERY STENOSIS. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 211-214.	1.9	3
142	RENIN GENE POLYMORPHISM ASSOCIATED WITH ALDOSTERONE RESPONSIVENESS TO THE RENINANGIOTENSIN SYSTEM IN PATIENTS WITH ALDOSTERONE-PRODUCING ADENOMAS. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 215-218.	1.9	14
143	AN ASSOCIATION OF PRIMARY ALDOSTERONISM AND ADRENALINE-SECRETING PHAEOCHROMOCYTOMA. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 219-222.	1.9	31
144	CORTISOL PRODUCTION BY ALDOSTERONE-PRODUCING ADENOMAS IN VITRO. Clinical and Experimental Pharmacology and Physiology, 1993, 20, 292-295.	1.9	15

#	ARTICLE	IF	CITATIONS
145	EVIDENCE THAT PRIMARY ALDOSTERONISM MAY NOT BE UNCOMMON: 12% INCIDENCE AMONG ANTIHYPERTENSIVE DRUG TRIAL VOLUNTEERS. Clinical and Experimental Pharmacology and Physiology, 1993, 20, 296-298.	1.9	176
146	ANGIOTENSIN-RESPONSIVEALDOSTERONE-PRODUCING ADENOMAS: POSTOPERATIVE DISAPPEARANCE OF ALDOSTERONE RESPONSE TO ANGIOTENSIN. Clinical and Experimental Pharmacology and Physiology, 1993, 20, 306-309.	1.9	21
147	FAMILIAL HYPERALDOSTERONISM TYPE II: FIVE FAMILIES WITH A NEW VARIETY OF PRIMARY ALDOSTERONISM. Clinical and Experimental Pharmacology and Physiology, 1992, 19, 319-322.	1.9	134
148	CLINICAL AND PATHOLOGICAL DIVERSITY OF PRIMARY ALDOSTERONISM, INCLUDING A NEW FAMILIAL VARIETY. Clinical and Experimental Pharmacology and Physiology, 1991, 18, 283-286.	1.9	127